Skip to main content
Article thumbnail
Location of Repository

Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries

By Yi-Ping Zhong, Ying Ying, Hai-Tao Wu, Can-Quan Zhou, Yan-Wen Xu, Qiong Wang, Jie Li, Xiao-Ting Shen and Jin Li


Aim. To compare the basic endocrine profile and outcomes of in vitro fertilization (IVF) in women with polycystic ovary syndrome (PCOS), ovulatory polycystic ovaries (PCO), or normal ovaries (NO). Methods. The basic clinical features and in vitro fertilization and embryo transfer outcome in patients receiving IVF or intracytoplasmic sperm injection (ICSI) were retrospectively analyzed. Results. The body mass index, basal luteinizing hormone, and testosterone levels were significantly lower in patients with ovulatory PCO compared to those in patients with PCOS. The PCOS patients exhibited the shortest duration of ovarian stimulation and lowest dose of gonadotropin, followed by the ovulatory PCO and NO patients. The ovulatory PCO and PCOS patients showed similar levels of E2 on the human chorionic gonadotropin treatment day and numbers of oocytes, which were both significantly higher than those of the NO patients. The fertilization rate of the PCOS patients was significantly lower than the other two groups. Compared to NO patients, the cleavage rate was lower in both PCOS and ovulatory PCO patients, however, the number of available embryos was significantly more in these two groups. The incidence of the moderate to severe ovarian hyperstimulation syndrome (OHSS) was markedly higher in the PCOS and ovulatory PCO patients. Conclusion. Ovulatory PCO patients do not express similar endocrine abnormalities as PCOS patients. Although the fertilization rate and cleavage rate were relatively low in PCOS patients, ultimately, all the three groups showed similar transferred embryo numbers, clinical pregnancy rates, and implantation rates. Since the incidence of OHSS was much higher in the PCOS and ovulatory PCO patients, we should take more care of these patients and try to prevent severe OHSS

Topics: Clinical Study
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1993). A .H .B a l e n ,S .L .T a n ,J .M a c D o u g a l l ,a n dH .S .J a c o b s , “Miscarriageratesfollowingin-vitrofertilizationareincreased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin,”
    2. (1997). A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome,” Fertility and Sterility,
    3. (2010). A.Swanton,L.Storey,E.McVeigh,andT.Child,“IVFoutcome inwomenwithPCOS,PCOandnormalovarianmorphology,”
    4. (2001). ang,M.J .Da vies,andR.J .N o rman,“P ol y cy stico varian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment,”
    5. (2005). Comparison of in vitro fertilization outcome in women with and without sonographic evidence of polycystic ovarian morphology,”
    6. (2008). Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome,”
    7. (2011). Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial,” Human Reproduction,
    8. (2010). ee ta l . ,“ Ac o m p a r a t i v es t u d y on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only
    9. (2003). Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome,”
    10. (1990). Hypersecretion of luteinising hormone, infertility, and miscarriage,”
    11. (2002). Impact of serum E2 levels and the number of retrieved oocytes on clinical outcome of in vitro fertilization and embryo transfer,”
    12. (2001). In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome,”
    13. (2003). Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome,”
    14. (2004). J¨ arvel¨ a ,P .S l a d k e v i c i u s ,S .K e l l y ,K .O j h a ,S .C a m p b e l l
    15. (2004). Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study,”
    16. (2005). Outcome of intracytoplasmic sperm injection in patients with
    17. (2004). Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome,”
    18. (1995). Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients,”
    19. (2009). r v i e t o ,S .M e l t c e r ,R .H o m b u r g ,R .N a h u m ,J .R a b i n s o n
    20. (1998). Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries,”
    21. (2010). The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance,”
    22. (1999). The prevalence of polycystic ovaries in women with infertility,”
    23. (2006). The use of metformin for women with
    24. (2010). VEGF modulates the effects of gonadotropins in granulosa cells,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.